Outset Medical Q3 2026 Earnings Conference Call - OUTSET MEDICAL INC

Explicit Guidance:

• FY 2026 Revenue: Reiterated range of $125 million to $130 million.
• FY 2026 Gross Margin: Expected to remain in the low 40% to mid 40% range; management notes that a higher mix of console sales could shift the result toward the lower end of this range.
• FY 2026 Cash Flow: On track to use approximately $40 million in cash for the full year (following $10.3 million use in Q3).
• Future Revenue Growth: Management aims to return to double-digit growth rates, with the H2 2026 guidance already incorporating significant growth rates.
• Company-Wide Margin Milestone: Progressing toward a target of 50% gross margin company-wide.
• FY 2027 Guidance: No specific financial guidance provided for 2027; management will discuss 2027 details in finer depth at the Q4 earnings report.
• CapEx Outlook: No major changes or expected slowdowns in capital spending environment for 2027 anticipated at this time.

Business-Segment Outlook:

• Refresh Opportunity: Identified as a primary growth driver representing an estimated $150 million revenue opportunity over the next several years, driven by over 3,000 consoles nearing end-of-life. Momentum is building with signed agreements (e.g., HCA) and active engagement with large health systems.
• Expansion Opportunities: Focus on "same-store" growth (adding consoles to specific units like ICU) and facility expansion within existing health system networks. All 14 largest health systems by estimated console opportunity are currently existing customers.
• Tableau Adoption: Targeting system-wide adoption across the nation's top 250 health systems and roughly half of the top 100 largest IVNs.
• Home Dialysis: Strategy focuses on long-term retention with a goal of maintaining >90% retention rates within the first 90 days. Growth driven by training speed and existing provider expansion into new home programs.
• Next-Gen Product: Full release preparations underway; prioritization is on high-quality customer experience over speed, with expectations to bring the product to market at scale in the coming months and quarters.
• Recurring Revenue: EMR offering is ramping and growing 23% year-over-year; overall recurring revenue growth trend remains positive.

Market and Competitive Outlook:

• Policy Tailwinds: The HHS "Kidney Care National Plan" is viewed as a positive development encouraging patient choice, expanding access to home dialysis, and reducing barriers for new entrants, aligning with Outset's mission.
• Competitive Landscape: Viewed as becoming more competitive and innovative due to federal initiatives aimed at addressing concentration and competition constraints in dialysis.
• Market Dynamics: Health systems face increasing pressure to reduce costs and elevate care quality, creating a compelling case for bringing dialysis in-house via the Tableau platform.
• Acute Market Strategy: Commercial focus redoubled on the top 250 Integrated Delivery Networks (IDNs) due to their large total addressable market (TAM) for both consoles and treatment volume.

Macro / Industry Outlook:

• Regulatory Environment: The HHS National Plan (launched two weeks prior) is expected to broaden patient access to home-based care and new technologies like Tableau, though specific implementation impacts remain to be seen.
• Capital Spending: No perceived immediate shifts or slowdowns in hospital capital spending climate affecting the outlook.
• Market Trends: Validation of clinical and financial benefits of in-house dialysis via dozens of recent abstracts and papers supports market acceptance.

Strategic Initiatives:

• Commercial Model Evolution: Reducing territory sizes to deepen relationships; realigning compensation incentives to drive commercial priorities; expanding the capital sales team regionally and at the national account level.
• Team Alignment: Executing a cross-functional strategy aligning sales, marketing, clinical service, and enterprise accounts around "one Outset" to accelerate adoption.
• Customer Retention: Leveraging high cumulative retention (96%) among parent customers with Tableau consoles to drive refresh, expansion, and new sales.
• Implementation Scale: Supporting transition from outsourced to insourced dialysis for top 10 US health systems with customized project plans, nurse training, and physician education.

Risks and Headwinds to Outlook:

• Product Mix: A higher mix of console sales could depress gross margins toward the lower end of the low 40% to mid 40% guidance range.
• Guidance Uncertainty: Management maintains discipline and does not raise guidance despite Q3 beats, citing dynamic pipeline and the need to set up future success; FY 2027 specifics remain undefined.
• Regulatory Implementation: The actual impact of the HHS Kidney Care National Plan depends on the specifics of its implementation, which could vary.
• Execution Risks: Success relies on continued execution of complex implementations, system-wide adoption, and the successful launch of the next-generation Tableau system.
• Competition/Barriers: While the environment is favorable, structural changes to competition and physician practices depend on ongoing federal and market evolution.

Management Tone on the Future:

• Confidence: High confidence in the "significant opportunity ahead" and belief that Outset is "well positioned to help lead that change."
• Strategic Focus: Emphasis on "execution" and "foundational work" to drive "predictable, profitable growth."
• Hesitation/Caution: Cautious optimism regarding the next-gen product launch (prioritizing quality over speed) and the macro impact of the HHS plan (awaiting implementation details).
• Commitment: Undivided focus on the "three console growth drivers" (refresh, expansion, new customers) and a clear intent to return to double-digit growth.

Miscellaneous:

• Customer Satisfaction: Recent "Voice of the Customer" assessment exceeded all healthcare benchmarks of the third-party consulting firm.
• Data Ecosystem: Tableau ecosystem now comprises over 10 trillion data points.
• Treatment Volume: Platform has supported over 4 million cumulative dialysis treatments.
• Financial Position: Ended Q3 2026 with $140.7 million in cash and equivalents.